

### **AMENDMENTS TO THE SPECIFICATION**

Please replace the paragraph beginning at page 1, line 14, with the following amended paragraph.

--The present invention was made with government support under Grant Nos. K08 HL03395, 1R01CA103320, and 1R01CA096651, awarded by the National Institutes of Health. The Government ~~may have~~ has certain rights in this invention--

Please replace the paragraph beginning at page 11, line 16, with the following amended paragraph.

-- ~~Figures 11A-11E~~ Figures 11A-11D. Administration of 1-MT enhances immune-mediated host anti-tumor effect when administered with radiation or cyclophosphamide. Mice were injected subcutaneously (SQ) with  $4 \times 10^4$  B16F10 cells. In Fig. 11A 1MT (20 mg/day of a DL racemic mixture) was administered SQ by continuous-release copolymer pellets, with or without 500 cGy of total-body  $\gamma$ -irradiation. Control mice received vehicle pellets without drug. In Fig. 11B 1MT was administered with cyclophosphamide (CPM) (150 mg/kg, one dose). Fig. 11C represents 1MT and cyclophosphamide in rag1-knockout hosts. Fig. 11D represents the more potent pure D-isomer of 1MT, given 5 mg/day, with cyclophosphamide.--